少人数グループによる円滑なディスカッションで、インタラクティブな参加により、フォーカスしたトピックに関する問題解決や将来のコラボレーションにつながります。

バズとは？

PepTalkのバズセッションは、上流工程のタンパク質の発現と生産から、下流工程のスケールアップと製造まで、重要かつ興味深いトピックについて、代表者が刺激的なディスカッションを展開します。共通の関心を持つさまざまな分野の科学者間で、ブレーンストーミングとインタラクティブな問題解決を行う、モデレーター進行型のディスカッションです。

火曜日 4:15 - 5:00 PM

Recombinant Protein Production Part 1

BuzZ Table 1: Getting the Math Right: Adding and Subtracting Post-Translational Modifications (PTMs) to Recombinant Proteins
Moderator: Christopher Cooper, PhD, Director and Head of Protein Sciences, CHARM Therapeutics

• Choosing an appropriate QC method for your budget
• Moving on from biotinupcoming alternative protein labelling technologies
• Challenges in addition of site-specific PTMs (e.g. phosphorylation) and protein PTMs (e.g. ubiquitin, SUMO)
• Advances in (de)glycosylation and its analysis

BuzZ Table 2: Improving Membrane Protein Yield and Quality
Moderator: Neha Bhat, PhD, Sr Scientist, Biologics Discovery, Johnson & Johnson Innovative Medicine

• Advancements in detergents and nanodisc technologies
• Emerging techniques to overcome instability
• High-throughput screening and process automation approaches
• Overcoming Glycosylation and Post-Translational Challenges
• Case studies and practical challenges

Automation in Protein Sciences

BuzZ Table 3: Balancing High-Throughput Expression with Data Capture/Analysis 
Moderator: James Kostas, Senior Scientist, Protein and Structural Chemistry, Merck

• How do we track data captured at every stage of the protein production lifecycle?
• Is higher throughput ALWAYS better or does it just push the bottleneck downstream?
• How do we connect, analyze, and correlate data from different sources (instruments, databases, e-notebooks) in order to draw conclusions from our data?
• How do we effectively QC HT data?
• How can we use our data to reduce the number of samples in future design-test-make cycles? 

BuzZ Table 4: Challenges in High-Throughput Production Platforms
Moderator: Kristoff Homan, PhD, Senior Principal Scientist, Discovery Biotherapeutics, Bristol-Myers Squibb Company

• HT production approaches
• Incorporating AI/ML predictions into workflows
• Challenges with emerging modalities
• Functional assessment of molecules

BuzZ Table 5: LIMS Level-Up
Moderators:
Emma Altman, Senior Research Associate, Protein Sciences, Kite, a Gilead Company
Nicole Cannon, Protein Sciences, Kite Pharma

• Tips, but no tricks, for starting a LIMS
• Data management pitfalls & solutions
• Limitations - where to draw the line?
• Reckless encouragement

Methods for Developability Analysis

BuzZ Table 6: Building the End-to-End Workflow in Analytical Development: Current and Future Technologies
Moderator: Kevin Zen, PhD, Director, Analytical Development, Opthea Limited

• High throughput analytics for developability workflow
• Immunogenicity prediction and ex vivo assays to assess immunogenicity
• Aggregation prediction and analytical technologies to assess aggregation propensity
• PTM prediction and analytical tools to assess molecular liability
• Balance between biological function and biophysical stability

BuzZ Table 7: AI and ML in Biotherapeutic Process Development and Manufacturing: Hype vs. Reality
Moderator: Carme Pons Royo, PhD, Postdoctoral Associate, Massachusetts Institute of Technology

• Realistic Expectations: Where does AI/ML provide the most value and where does it fall short in bioprocessing. 
• Feasibility: How practical are these tools for biologics manufacturing?
• Upstream Applications: Can AI/ML improve cell culture optimization, media selection, and yield prediction?
• Downstream Relevance: How AI can assist with purification, process scaling, and troubleshooting bottlenecks?
• Analytics and Monitoring: Using AI to predict product stability, aggregation, and monitor CQAs in continuous manufacturing.
• Integration Strategies: Practical tips for validating and embedding AI/ML models into existing workflows.

Targeted Radioligand Therapies

BuzZ Table 8: Challenges in the Production and Distribution of Short-Lived Radiopharmaceuticals
Moderator: Arshad Ahmed, Founder & CEO, Zaylan Associates

• Time constraints from production, QC to delivery
• Pros and cons of decentralized production
• The need for specialized production facilities and highly skilled personnel 
• Regulatory compliance 
• Supply chain logistics 
• Waste management
  

木曜日 7:30 - 8:15 AM

Recombinant Protein Production Part 2

BuzZ Table 1: Therapeutic Protein Production: Innovations and Best Practices
Moderator: Robert M. Hughes, PhD, Associate Professor, Chemistry, East Carolina University

• Construct Design and Misfolding Prevention
• Leveraging Machine Learning and Data Optimization
• Cell-Free Systems for Complex Protein Synthesis

BuzZ Table 2: Common Issues with Protein Production
Moderators:
Richard Altman, MS, Field Application Scientist, Life Science Solutions, Thermo Fisher Scientific
Henry C. Chiou, PhD, Senior Director General Manager, Biosciences, Thermo Fisher Scientific  (Recently Retired)

• What are the current challenges to protein production?
• How do we optimize the whole protein expression workflow process?
• How can we maintain volumetric yields while scaling expression up or down?
• What cell line(s) should we use and when?
• What parameters can impact the quality or physical attributes of produced proteins?
• What are the obstacles and potential solutions for transient protein production?

Cutting-Edge Tools for Purification and Quality Assurance

BuzZ Table 3: Towards Wholly de novo Proteins
Moderator: Cole A. DeForest, PhD, Weyerhaeuser Endowed Professor and Associate Chair, Department of Chemical Engineering, University of Washington

• Computational protein design
• Non-canonical amino acid incorporation via genetic code expansion
• Engineered cell lines and non-traditional expression hosts

BuzZ Table 4: Special Challenges in Routine Protein Production
Moderator: David Wood, PhD, Co-Founder, CSO, Protein Capture Science; Professor, Chemical & Biomolecular Engineering, The Ohio State University

• When you needed the protein yesterday - high pressure production
• How things change when this protein may be headed for the clinic
• Out of left field - strange things that proteins do, and what to do back

Characterization for Novel Biotherapeutics

BuzZ Table 5: Multiple Challenges for Multispecific Antibodies
Moderator: Meghan M. Verstraete, PhD, Scientist, Protein Engineering, Zymeworks, Inc.

• Prioritizing parameters to screen in early discovery (format, paratopes, affinity, valency, etc.)
• Purification and characterization of multispecific antibodies and product-related impurities
• Challenges with benchmarking developability criteria for multispecific antibodies
• Pros and cons of multispecific antibody therapeutics vs. combination of bispecific/monospecific therapeutics

BuzZ Table 7: Challenges in Intracellular Delivery of Proteins/Peptides
Moderator: Joseph E Pazzi, Director of Formulation, reThink64 Bionetworks

• What Proteins/Peptides with intracellular targets are on the market?
• What are current approaches for penetrating the cell membrane?
• Pros and cons of current approaches like CCPs, nanodiscs, LNPs, pcAAVs?
• What are the major challenges in cell membrane penetration and tissue localization? 

Next-Generation Protein Degradation

BuzZ Table 6: Multispecific Antibody Design and Production Strategies for Maximizing Target and Tissue Selectivity
Moderator: Andy Goodrich, PhD, Associate Director, Biologics, Epibiologics

• Protein design and degrader selection strategies to enhance tissue selectivity
• Antibody developability assessments to ensure specificity and drug-like properties
• Multispecific protein production and purification from screening through manufacturing
  

These are forums for open discussion of protein-related challenges, and not sales opportunities. We emphasize that these breakout groups are for interactive discussions among scientists and are not meant to be, in any way, a corporate or product discussion. Topics can be limited to one protein area or may address issues which cross over the borders between pipeline conference topics. Moderators should be well-versed in the topic area and able to keep the discussion focused and productive. BuzZ Sessions are IN-PERSON ONLY.

Continue to check back for topics updates.